Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

How COVID-19 sidelined top vaccine manufacturers  

By Brian Buntz | March 2, 2021

COVID-19 vaccinePfizer/BioNTech and Moderna were the first to win emergency use authorization from FDA for COVID-19 vaccines. Johnson & Johnson recently got its own permission to distribute its vaccine.

But other Big Pharma companies have struggled to get vaccines to the finish line, including some of the world’s largest vaccine makers such as GlaxoSmithKline, Merck and Sanofi.

While the pandemic offers pharmaceutical companies a unique opportunity to curry favor with the public and politicians, the current dearth of vaccines is partly a result of Big Pharma companies being “missing in action,” according to Zain Rizvi, a pharma-focused researcher at Public Citizen researcher, quoted in Financial Times.

COVID-19 vaccines could be a cash cow for Pfizer and Moderna. The former expects to rake in $15 billion worth of vaccines this year, while Moderna has forecasted $18.4 billion in sales.

Smaller vaccine companies such as Moderna, BioNTech and Novavax have seen their stock increase dramatically since the beginning of the pandemic. In contrast, GSK, Merck and Sanofi have seen stock slides in the range of 13% to 30%.

GSK and Sanofi

While in 2018, GlaxoSmithKline noted in a press release that the joint venture with Pfizer would enable it to increase its focus on vaccines, the company struggled in 2020 to stand up a COVID-19 vaccine business. In December, GSK and GlaxoSmithKline confirmed a delay in their adjuvanted recombinant protein-based COVID-19 vaccine owing to an inadequate immune response in older adults in a Phase 1/2 trial.

Sanofi has since agreed with Pfizer and BioNTech to support the manufacturing of their vaccine.

GSK and Sanofi are continuing to work on a COVID-19 vaccine candidate. GSK is also taking a page out of Pfizer’s playbook — partnering with upstart German biotech to develop an mRNA COVID-19 vaccine.

Merck

After scrapping its own COVID-19 vaccine development efforts, Merck has agreed to support Johnson & Johnson vaccine production.

Merck is also working to commercialize a COVID-19 biological therapeutic known as CD24Fc that it acquired from OncoImmune.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio
Dollars for drugs
Democrats’ drug pricing plan attracts pushback from Republicans
GBT/Pfizer
Pfizer to scoop up Global Blood Therapeutics for $5.4 billion 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards